These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 7690358)

  • 1. Direct inhibitory effect of somatostatin on the growth of the human prostatic cancer cell line LNCaP: possible mechanism of action.
    Brevini TA; Bianchi R; Motta M
    J Clin Endocrinol Metab; 1993 Sep; 77(3):626-31. PubMed ID: 7690358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP.
    Limonta P; Dondi D; Moretti RM; Maggi R; Motta M
    J Clin Endocrinol Metab; 1992 Jul; 75(1):207-12. PubMed ID: 1320049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autocrine regulation of human prostate carcinoma cell proliferation by somatostatin through the modulation of the SH2 domain containing protein tyrosine phosphatase (SHP)-1.
    Zapata PD; Ropero RM; Valencia AM; Buscail L; López JI; Martín-Orozco RM; Prieto JC; Angulo J; Susini C; López-Ruiz P; Colás B
    J Clin Endocrinol Metab; 2002 Feb; 87(2):915-26. PubMed ID: 11836342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcitonin stimulates growth of human prostate cancer cells through receptor-mediated increase in cyclic adenosine 3',5'-monophosphates and cytoplasmic Ca2+ transients.
    Shah GV; Rayford W; Noble MJ; Austenfeld M; Weigel J; Vamos S; Mebust WK
    Endocrinology; 1994 Feb; 134(2):596-602. PubMed ID: 8299557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of luteinizing hormone-releasing hormone mRNA in the human prostatic cancer cell line LNCaP.
    Limonta P; Dondi D; Moretti RM; Fermo D; Garattini E; Motta M
    J Clin Endocrinol Metab; 1993 Mar; 76(3):797-800. PubMed ID: 8445038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145.
    Moretti RM; Marelli MM; Dondi D; Poletti A; Martini L; Motta M; Limonta P
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3930-7. PubMed ID: 8923840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activin inhibits basal and androgen-stimulated proliferation and induces apoptosis in the human prostatic cancer cell line, LNCaP.
    Wang QF; Tilly KI; Tilly JL; Preffer F; Schneyer AL; Crowley WF; Sluss PM
    Endocrinology; 1996 Dec; 137(12):5476-83. PubMed ID: 8940374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers.
    Rekasi Z; Varga JL; Schally AV; Halmos G; Armatis P; Groot K; Czompoly T
    Endocrinology; 2000 Jun; 141(6):2120-8. PubMed ID: 10830299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin up-regulates topoisomerase II alpha expression and affects LNCaP cell cycle.
    Brevini-Gandolfi TA; Cillo F; Favetta LA; Montagna A; Motta M
    Mol Cell Endocrinol; 2001 May; 176(1-2):103-10. PubMed ID: 11369449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest.
    Kokontis JM; Hay N; Liao S
    Mol Endocrinol; 1998 Jul; 12(7):941-53. PubMed ID: 9658399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
    Igawa T; Lin FF; Rao P; Lin MF
    Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-proliferative effect of the kinase inhibitor K252a on human prostatic carcinoma cell lines.
    Delsite R; Djakiew D
    J Androl; 1996; 17(5):481-90. PubMed ID: 8957691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation.
    Zhuang SH; Burnstein KL
    Endocrinology; 1998 Mar; 139(3):1197-207. PubMed ID: 9492054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dinaline inhibits amino acid transport and proliferation of colon carcinoma cells in vitro.
    Schaider H; Haberkorn U; Stöhr M; Berger MR
    Anticancer Res; 1995; 15(6B):2501-9. PubMed ID: 8669814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of LHRH agonists on the growth of human prostatic tumor cells: "in vitro" and "in vivo" studies.
    Montagnani Marelli M; Moretti RM; Dondi D; Limonta P; Motta M
    Arch Ital Urol Androl; 1997 Sep; 69(4):257-63. PubMed ID: 9396187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiproliferative action of melatonin on human prostate cancer LNCaP cells.
    Moretti RM; Marelli MM; Maggi R; Dondi D; Motta M; Limonta P
    Oncol Rep; 2000; 7(2):347-51. PubMed ID: 10671684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resveratrol induces prostate cancer cell entry into s phase and inhibits DNA synthesis.
    Kuwajerwala N; Cifuentes E; Gautam S; Menon M; Barrack ER; Reddy GP
    Cancer Res; 2002 May; 62(9):2488-92. PubMed ID: 11980638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1alpha,25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetate.
    Esquenet M; Swinnen JV; Heyns W; Verhoeven G
    Prostate; 1996 Mar; 28(3):182-94. PubMed ID: 8628721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct inhibitory effects of a somatostatin analog, SMS 201-995, on AR4-2J cell proliferation via pertussis toxin-sensitive guanosine triphosphate-binding protein-independent mechanism.
    Viguerie N; Tahiri-Jouti N; Ayral AM; Cambillau C; Scemama JL; Bastié MJ; Knuhtsen S; Estève JP; Pradayrol L; Susini C
    Endocrinology; 1989 Feb; 124(2):1017-25. PubMed ID: 2563240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
    Skowronski RJ; Peehl DM; Feldman D
    Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.